MAM
BNTX icon

Mark Asset Management’s BioNTech BNTX Stock Holding History

Mark Asset Management’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,000
Closed -$3M – 55
2022
Q4 		$3M Buy
+20,000
New +$3.08M 0.68% 40
2022
Q1 		– Sell
-10,000
Closed -$2.58M – 48
2021
Q4 		$2.58M Buy
+10,000
New +$2.74M 0.29% 38

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return

Mark Asset Management's BNTX Position: Q3 2023 in Review

Mark Asset Management sold out of BioNTech (BNTX) in Q3 2023, closing a stake of 22,920 shares — an estimated $2.47M sold.

Mark Asset Management first reported a position in BNTX in Q3 2021 and held it in 8 quarters. The position peaked at $23.2M in Q4 2021. 252 funds tracked by Wall St. Rank hold BNTX as of Q3 2023.

  • Mark Asset Management reported no remaining BioNTech position as of Q3 2023 after selling out during the quarter.
  • Mark Asset Management sold 22,920 BioNTech shares in Q3 2023, an estimated $2.47M.
  • Mark Asset Management first reported a position in BioNTech in Q3 2021 and held it in 8 quarters.
  • Mark Asset Management's BioNTech position peaked at $23.2M in Q4 2021.
  • 252 funds tracked by Wall St. Rank held BioNTech as of Q3 2023.

Based on Mark Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.